The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow. Generally, this predisposes the elderly to thrombosis rather than bleeding. It often necessitates antiplatelet or anticoagulation therapy, which can cause significant bleeding problems in an aging population. Additionally, changing renal function, modification in immune regulation, and a multitude of other disease processes, can give rise to acquired bleeding disorders. Bleeding can prove difficult to treat in a dynamic environment and in a population that may have underlying thrombotic risk factors.This article discusses some specific challenges of acquired bleeding arising in the elderly. The use of anticoagulation and nonsteroidal anti-inflammatory medications is prevalent in the treatment of the elderly and predisposes them to increased bleeding risk as their physiology changes. When prescribing and monitoring these therapies, it is exceedingly important to weigh thrombotic versus bleeding risks. There are additional rare acquired bleeding disorders that predominantly affect the elderly. One of them is acquired hemophilia, which is an autoimmune disorder arising from antibodies against factor VIII. The treatment challenge rests in the use of hemostatic agents in a population that is already at increased risk for thrombotic complications. Another rare disorder of intensifying interest, acquired von Willebrand syndrome, has a multitude of etiologic mechanisms. Understanding the underlying pathophysiology is essential in making a treatment decision for this disorder.

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2015.1.231DOI Listing

Publication Analysis

Top Keywords

acquired bleeding
16
bleeding disorders
12
bleeding
8
acquired
6
elderly
5
disorders elderly
4
elderly hemostatic
4
hemostatic balance
4
balance changes
4
changes advancing
4

Similar Publications

Objective: Periventricular anastomosis (PA), a recently recognized cause of hemorrhage in moyamoya disease, is reducible after bypass surgery. The timing of the reduction, however, remains poorly understood. The objectives of the present study were to demonstrate radiological reduction of PA occurring within 48 hours after surgery and to identify factors associated with reduction.

View Article and Find Full Text PDF

Background: The Georgian Birth Registry (GBR) is a comprehensive digital birth registry covering 99.8% of births nationwide. By law, registration in the GBR is mandatory, with data primarily transferred from medical records (MRs) by designated personnel at medical facilities.

View Article and Find Full Text PDF

Acquired von Willebrand syndrome (aVWS) is a rare hematological disorder depicted by dysfunctional or deficient von Willebrand factor activity and can be associated with underlying hematological malignancies such as non-Hodgkins lymphoma (NHL). This case report examines a patient with aVWS secondary to NHL and highlights the challenges in managing bleeding and optimizing a patient for surgery. The case report will explore the multidisciplinary approach to recognizing aVWS, treatment modalities, and adjunctive measures to reduce bleeding risk as well as long-term management.

View Article and Find Full Text PDF

Unlabelled: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet counts with increased risk of bleeding. In particular, ITP induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been increasingly reported. Since immunosuppressive regimens in organ transplantation are often the primary cause of increased risk of infection, ITP following solid organ transplantation has occasionally been observed.

View Article and Find Full Text PDF

Background: Zidovudine is an antiviral drug used to treat acquired immune deficiency syndrome (AIDS). Anaemia is a common adverse effect of zidovudine that usually occurs in the first 2 to 4 weeks of initial treatment. Here, we describe a patient with HIV infection who developed severe aplastic anaemia 11 years after taking zidovudine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!